scholarly journals Preexisting memory CD4+ T cells contribute to the primary response in an HIV-1 vaccine trial

2021 ◽  
Vol 131 (23) ◽  
Author(s):  
Suzanne L. Campion ◽  
Elena Brenna ◽  
Elaine Thomson ◽  
Will Fischer ◽  
Kristin Ladell ◽  
...  
2021 ◽  
Vol 22 (2) ◽  
pp. 912
Author(s):  
Nabila Seddiki ◽  
John Zaunders ◽  
Chan Phetsouphanh ◽  
Vedran Brezar ◽  
Yin Xu ◽  
...  

HIV-1 infection rapidly leads to a loss of the proliferative response of memory CD4+ T lymphocytes, when cultured with recall antigens. We report here that CD73 expression defines a subset of resting memory CD4+ T cells in peripheral blood, which highly express the α-chain of the IL-7 receptor (CD127), but not CD38 or Ki-67, yet are highly proliferative in response to mitogen and recall antigens, and to IL-7, in vitro. These cells also preferentially express CCR5 and produce IL-2. We reasoned that CD73+ memory CD4+ T cells decrease very early in HIV-1 infection. Indeed, CD73+ memory CD4+ T cells comprised a median of 7.5% (interquartile range: 4.5–10.4%) of CD4+ T cells in peripheral blood from healthy adults, but were decreased in primary HIV-1 infection to a median of 3.7% (IQR: 2.6–6.4%; p = 0.002); and in chronic HIV-1 infection to 1.9% (IQR: 1.1–3%; p < 0.0001), and were not restored by antiretroviral therapy. Moreover, we found that a significant proportion of CD73+ memory CD4+ T cells were skewed to a gut-homing phenotype, expressing integrins α4 and β7, CXCR3, CCR6, CD161 and CD26. Accordingly, 20% of CD4+ T cells present in gut biopsies were CD73+. In HIV+ subjects, purified CD73+ resting memory CD4+ T cells in PBMC were infected with HIV-1 DNA, determined by real-time PCR, to the same level as for purified CD73-negative CD4+ T cells, both in untreated and treated subjects. Therefore, the proliferative CD73+ subset of memory CD4+ T cells is disproportionately reduced in HIV-1 infection, but, unexpectedly, their IL-7 dependent long-term resting phenotype suggests that residual infected cells in this subset may contribute significantly to the very long-lived HIV proviral DNA reservoir in treated subjects.


Retrovirology ◽  
2013 ◽  
Vol 10 (1) ◽  
pp. 119 ◽  
Author(s):  
Camille L Novis ◽  
Nancie M Archin ◽  
Maria J Buzon ◽  
Eric Verdin ◽  
June L Round ◽  
...  

2009 ◽  
Vol 106 (47) ◽  
pp. 19940-19945 ◽  
Author(s):  
A. Benlahrech ◽  
J. Harris ◽  
A. Meiser ◽  
T. Papagatsias ◽  
J. Hornig ◽  
...  

Retrovirology ◽  
2012 ◽  
Vol 9 (S2) ◽  
Author(s):  
MJ Bunders ◽  
C van der Loos ◽  
PL Klarenbeek ◽  
J van Hamme ◽  
J Wilde ◽  
...  

Blood ◽  
2007 ◽  
Vol 110 (13) ◽  
pp. 4161-4164 ◽  
Author(s):  
Suha Saleh ◽  
Ajantha Solomon ◽  
Fiona Wightman ◽  
Miranda Xhilaga ◽  
Paul U. Cameron ◽  
...  

Latent HIV-1 infection of resting memory CD4+ T cells represents the major barrier to HIV-1 eradication. To determine whether the CCR7 ligands involved in lymphocyte migration can alter HIV-1 infection of resting CD4+ T cells, we infected purified resting CD4+ T cells after incubation with the chemokines CCL19 and CCL21. Incubation with CCL19 or CCL21 did not alter markers of T-cell activation or proliferation. However, after HIV-1 infection of CCL19- or CCL21-treated CD4+ T-cells, we observed low-level HIV-1 production but high concentrations of integrated HIV-1 DNA, approaching that seen in mitogen-stimulated T-cell blasts. Restimulation of CCL19-treated infected CD4+ T cells resulted in virus production consistent with establishment of postintegration latency. CCR7 ligands facilitate efficient entry of HIV-1 into resting CD4+ T cells. These studies demonstrate a unique action of the chemokines CCL19 and CCL21 and provide a novel model with which to study HIV-1 latency in vitro.


Sign in / Sign up

Export Citation Format

Share Document